November 2026

aod-9604 missed the october 28 hhs list — the trial that explains why

On October 28, 2026, [HHS issued an enforcement discretion policy](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) naming six peptides that licensed 503A compounding pharmacies could keep producing while formal FDA rulemaking continues: BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax. AOD-9604 was not on that list. It was not an oversight. This is a peptide that actually ran a phase 2b obesity trial in humans — a real clinical program funded by a pharma company that believed in the drug. The trial failed to demonstrate significant weight loss versus placebo, the company walked away from development, and the negative dataset has been in the literature since the mid-2000s. TikTok has no memory of that. It has only the promise: 'all the fat loss of HGH, none of the insulin disruption.' That framing predates the Oct 28 policy, predates the FDA's 2023 Category 2 placement, and predates the December 2024 advisory committee vote that went against it. The internet is still at step one of a story that reached step five a long time ago.

The molecule

aod-9604 is a growth-hormone fragment designed to trigger lipolysis without the full gh endocrine profile

AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone — residues 176–191 of the 191-amino-acid HGH molecule — developed through research at Monash University in Melbourne and advanced by Metabolic Pharmaceuticals, a spinout from the same institution. The original hypothesis was that this fragment carried the lipolysis-signaling properties of the full hormone without binding to the IGF-1 receptor that drives growth promotion, insulin resistance, and the endocrine side effects that complicate full GH administration. In animal models the idea showed real traction: rodent studies found the fragment reduced body fat in obese mice and improved metabolic markers, and in vitro work documented adipocyte-level fat-breakdown effects. [PubMed's AOD-9604 literature](https://pubmed.ncbi.nlm.nih.gov/?term=AOD-9604) contains both the preclinical work that generated enthusiasm and the human data that followed. The mechanistic rationale for GH-fragment lipolysis is not invented. What it could not guarantee was that a coherent animal mechanism translates into durable weight loss in a human body with competing systems and metabolic homeostasis working in every direction at once.

The phase 2b receipt

a 536-person trial ended development — the negative data record is complete

The phase 2b trial — the decisive one — enrolled approximately 536 participants over roughly 24 weeks, a serious clinical investment for a peptide compound. The primary endpoint was weight loss versus placebo. It did not get there: the trial failed to demonstrate statistically significant weight loss, and Metabolic Pharmaceuticals subsequently ended the development program. This is not a compound that has never been studied — it is a compound that was studied, reached the most consequential trial stage, and produced a negative result. [ClinicalTrials.gov's AOD-9604 registry](https://clinicaltrials.gov/search?term=AOD-9604) documents the trial footprint. The difference between 'this peptide has human trial data' and 'this peptide's trial data confirmed the fat-loss claim' is the entire story, and most of the online conversation collapses those two things into one sentence.

The regulatory trail

category 2 since 2023, excluded from the october 2026 enforcement discretion, on the wada 2026 prohibited list

In September 2023, the FDA moved AOD-9604 to its Category 2 bulk drug substances list — a designation for compounds presenting significant safety risks or lacking a clinical need that approved products cannot meet — formally prohibiting its use in pharmacy compounding. In December 2024, the FDA Pharmacy Compounding Advisory Committee voted against recommending 503A nomination for AOD-9604, confirming the placement through the advisory process. [The FDA's current bulk drug safety page](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) documents where AOD-9604 sits. The October 2026 HHS enforcement discretion extended provisional compounding access to six peptides; AOD-9604 was excluded. WADA's 2026 prohibited list classifies it under Section S2.2.3 as a GH fragment, prohibited in-competition and out-of-competition for all athletes under anti-doping rules — a classification reflecting concern about growth-hormone-axis manipulation independent of any efficacy finding. A lawsuit filed in the Northern District of Texas by Evexias and FarmaKeio challenged the Category 2 placement for a group of peptides including AOD-9604; that litigation was pending as of this writing, and legal challenges do not alter the clinical dataset.

Early human — PeptideFactCheck stance

the trial failure is the receipt — 'has been researched' is not the same as 'research confirmed the benefit'

AOD-9604 holds PeptideFactCheck's Early human evidence tier: interesting enough to watch, too early for broad certainty — meaning the human investigation did happen, the results are documented, and they did not validate the primary fat-loss claim that drives most of the current online interest. Some early human safety and tolerability work documented acceptable profiles; [the peer-reviewed safety literature](https://jofem.org/index.php/jofem/article/view/157) exists. The lipolysis mechanism theory has a basis in fragment pharmacology. The connection between that mechanism and meaningful weight loss in humans is precisely what the phase 2b trial tested — and what it failed to demonstrate. The internet version collapses 'backed by research' into confirmation, when the research's most direct result was a qualified no. Seventeen years after the trial ended and the development program closed, the compound is back on TikTok riding the GLP-1 cultural moment, marketed on a promise the trial did not keep. The receipt still exists; it is in the trial record.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.